BLUE BELL, Pa.--(BUSINESS WIRE)--Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the presentation of recent preclinical data using its next generation of minimally invasive intradermal (skin) electroporation delivery devices at the Phacilitate Vaccine Forum 2011 in Washington, DC. The presentation, titled “Potent cellular responses to SynCon™ DNA vaccines targeting traditional prophylactic vaccine targets,” was made by Dr. Niranjan Y. Sardesai, Inovio’s Sr. VP of Research and Development, and highlighted recent developments made by Inovio to improve the immune potency, usability, and tolerability of DNA vaccines delivered by electroporation.
